174 related articles for article (PubMed ID: 21257009)
1. Analysis of willingness to pay for implantable cardioverter-defibrillator therapy.
Nowakowska D; Guertin JR; Liu A; Abrahamowicz M; Lelorier J; Lespérance F; Brophy JM; Rinfret S
Am J Cardiol; 2011 Feb; 107(3):423-7. PubMed ID: 21257009
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of implantable cardioverter defibrillators in patients >or=65 years of age.
Sanders GD; Kong MH; Al-Khatib SM; Peterson ED
Am Heart J; 2010 Jul; 160(1):122-31. PubMed ID: 20598982
[TBL] [Abstract][Full Text] [Related]
3. Willingness to pay to eliminate the risk of restenosis following percutaneous coronary intervention: a contingent valuation.
Guertin JR; Liu A; Abrahamowicz M; Cohen DJ; Ismail S; LeLorier J; Brophy JM; Rinfret S
Circ Cardiovasc Qual Outcomes; 2011 Jan; 4(1):46-52. PubMed ID: 21156881
[TBL] [Abstract][Full Text] [Related]
4. Valuing a hypothetical cure for rheumatoid arthritis using the contingent valuation methodology: the patient perspective.
Fautrel B; Clarke AE; Guillemin F; Adam V; St-Pierre Y; Panaritis T; Fortin PR; Menard HA; Donaldson C; Penrod JR
J Rheumatol; 2005 Mar; 32(3):443-53. PubMed ID: 15742435
[TBL] [Abstract][Full Text] [Related]
5. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.
Yao G; Freemantle N; Calvert MJ; Bryan S; Daubert JC; Cleland JG
Eur Heart J; 2007 Jan; 28(1):42-51. PubMed ID: 17110403
[TBL] [Abstract][Full Text] [Related]
6. Willingness to pay for on-demand and prophylactic treatment for severe haemophilia in Sweden.
Carlsson KS; Höjgård S; Lethagen S; Lindgren A; Berntorp E; Lindgren B
Haemophilia; 2004 Sep; 10(5):527-41. PubMed ID: 15357780
[TBL] [Abstract][Full Text] [Related]
7. Willingness to pay for avoiding coronary restenosis and repeat revascularization: results from a contingent valuation study.
Greenberg D; Bakhai A; Neumann PJ; Cohen DJ
Health Policy; 2004 Nov; 70(2):207-16. PubMed ID: 15364150
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
Mark DB; Nelson CL; Anstrom KJ; Al-Khatib SM; Tsiatis AA; Cowper PA; Clapp-Channing NE; Davidson-Ray L; Poole JE; Johnson G; Anderson J; Lee KL; Bardy GH;
Circulation; 2006 Jul; 114(2):135-42. PubMed ID: 16818817
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of implantable cardioverter-defibrillators.
Sanders GD; Hlatky MA; Owens DK
N Engl J Med; 2005 Oct; 353(14):1471-80. PubMed ID: 16207849
[TBL] [Abstract][Full Text] [Related]
10. Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy.
You JJ; Woo A; Ko DT; Cameron DA; Mihailovic A; Krahn M
Am Heart J; 2007 Nov; 154(5):899-907. PubMed ID: 17967596
[TBL] [Abstract][Full Text] [Related]
11. Quality of life among implantable cardioverter-defibrillator recipients in the primary prevention therapeutic era.
Groeneveld PW; Matta MA; Suh JJ; Yang F; Shea JA
Pacing Clin Electrophysiol; 2007 Apr; 30(4):463-71. PubMed ID: 17437568
[TBL] [Abstract][Full Text] [Related]
12. Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS).
Bokhari F; Newman D; Greene M; Korley V; Mangat I; Dorian P
Circulation; 2004 Jul; 110(2):112-6. PubMed ID: 15238454
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population.
Chan PS; Stein K; Chow T; Fendrick M; Bigger JT; Vijan S
J Am Coll Cardiol; 2006 Jul; 48(1):112-21. PubMed ID: 16814657
[TBL] [Abstract][Full Text] [Related]
14. Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population.
Cowie MR; Marshall D; Drummond M; Ferko N; Maschio M; Ekman M; de Roy L; Heidbuchel H; Verboven Y; Braunschweig F; Linde C; Boriani G
Europace; 2009 Jun; 11(6):716-26. PubMed ID: 19359333
[TBL] [Abstract][Full Text] [Related]
15. Willingness to pay for social health insurance among informal sector workers in Wuhan, China: a contingent valuation study.
Bärnighausen T; Liu Y; Zhang X; Sauerborn R
BMC Health Serv Res; 2007 Jul; 7():114. PubMed ID: 17659084
[TBL] [Abstract][Full Text] [Related]
16. Patients' willingness to pay for pharmacist-provided menopause and hormone replacement therapy consultations.
Barner JC; Branvold A
Res Social Adm Pharm; 2005 Mar; 1(1):77-100. PubMed ID: 17138467
[TBL] [Abstract][Full Text] [Related]
17. Reliability of self-reported willingness-to-pay and annual income in patients treated for toenail onychomycosis.
Cham PM; Chen SC; Grill JP; Jonk YC; Warshaw EM
Br J Dermatol; 2007 May; 156(5):922-8. PubMed ID: 17459013
[TBL] [Abstract][Full Text] [Related]
18. Proportion of patients needing an implantable cardioverter defibrillator on the basis of current guidelines: impact on healthcare resources in Italy and the USA. Data from the ALPHA study registry.
Pedretti RF; Curnis A; Massa R; Morandi F; Tritto M; Manca L; Occhetta E; Molon G; De Ferrari GM; Sarzi Braga S; Raciti G; Klersy C; Salerno-Uriarte JA;
Europace; 2010 Aug; 12(8):1105-11. PubMed ID: 20400768
[TBL] [Abstract][Full Text] [Related]
19. Impact of age and medical comorbidity on the effectiveness of implantable cardioverter-defibrillators for primary prevention.
Chan PS; Nallamothu BK; Spertus JA; Masoudi FA; Bartone C; Kereiakes DJ; Chow T
Circ Cardiovasc Qual Outcomes; 2009 Jan; 2(1):16-24. PubMed ID: 20031808
[TBL] [Abstract][Full Text] [Related]
20. Microvolt T-wave alternans and the selective use of implantable cardioverter defibrillators for primary prevention: a cost-effectiveness study.
Filion KB; Xie X; van der Avoort CJ; Dendukuri N; Brophy JM
Int J Technol Assess Health Care; 2009 Apr; 25(2):151-60. PubMed ID: 19331707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
